Heart Valve Technology

This channel includes news and new device innovations about heart valve technologies, including the aortic valve, mitral valve, pulmonic valve, and tricuspid valve. This includes information on transcatheter valve technologies like transcatheter aortic valve replacement (TAVR, or implantation TAVI), transcatheter mitral valve repair or replacement (TMVR), transcatheter and surgical valve repairs, and surgical replacement valves. Newer devices are now being used for transcatheter tricuspid valve repair replacement (TTVR). 

Videos | Structural Heart

Dr. Neil Moat, MBBS, chief medical officer of Abbott's structural heart business, was a cardiac surgeon specializing in ...

Home October 15, 2021
Home
News | Computed Tomography (CT)

October 14, 2021 — Cardiac computed tomography angiography (CTA) derived left atrium emptying fraction (LAEF) improves ...

Home October 14, 2021
Home
Videos | Structural Heart

Tiberio Frisoli, M.D., interventional structural cardiologist, senior staff physician, Henry Ford Hospital, explains how ...

Home October 14, 2021
Home
News | Cath Lab

October 6, 2021 — Boston Scientific Corp. announced it entered into a definitive agreement to acquire Baylis Medical ...

Home October 06, 2021
Home
Two of the top technology headlines this past month was the FDA clearance of the Abbott Portico transcatheter aortic valve replacement (TAVR) device, and the first women to receive a Carmat artificial heart.
Feature | BY Dave Fornell, DAIC Editor

October 6, 2021 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC) ...

Home October 06, 2021
Home
Videos | Structural Heart

Tom Jones, M.D., director, cardiac cath labs, Seattle Children’s Hospital, and principle investigator of the Medtronic ...

Home September 28, 2021
Home
Videos | Structural Heart

Dr. Neil Moat, MBBS, chief medical officer of Abbott's structural heart business, explains the latest advances in Abbott ...

Home September 20, 2021
Home
The U.S. Food and Drug Administration (FDA) has cleared the company's Portico with FlexNav transcatheter aortic valve replacement (TAVR) system to treat people with symptomatic, severe aortic stenosis who are at high or extreme risk for open-heart surgery. 
Feature | Structural Heart Occluders | By Dave Fornell, Editor

September 20, 2021 — Abbott announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Portico ...

Home September 20, 2021
Home
News | Antiplatelet and Anticoagulation Therapies

September 1, 2021 – The anticoagulant edoxaban (Savaysa) may be just as effective as warfarin for preventing heart ...

Home September 01, 2021
Home
News | Vascular Closure Devices

July 15, 2021 — Vivasure Medical announced its development program for PerQseal Blue, a sutureless and fully ...

Home July 15, 2021
Home
Videos | Structural Heart

Doctor Andreas Ruck, interventional cardiologist and head of the mitral/tricuspid program, Karolinska University ...

Home July 14, 2021
Home
The Xeltis synthetic polymer restorative pulmonary valve is implanted surgically and acts as a scaffold for the patient's own cells to proliferate. The valve and conduit then bioresorbs over time, leaving behind a new valve made from the patient's own cells. The hope is this will reduce or eliminate the need for numerous repeat surgeries as a pediatric patient grows.
Feature | Heart Valve Technology

July 8, 2021 – Xeltis announced it started the first pivotal trial for a synthetic polymer restorative pulmonary valve ...

Home July 08, 2021
Home
News | Structural Heart

June 29, 2021 – Cardiologists at Beaumont Health successfully replaced a 34-year-old woman’s tricuspid valve in a rare ...

Home June 29, 2021
Home
Blog | Structural Heart

It is brutal and very expensive to bring a new transcatheter valve to market. Boston Scientific invested vast amounts of ...

Home June 08, 2021
Home
Subscribe Now